Fractyl Health, Inc. (NASDAQ:GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced additions to its U.S. patent portfolio that strengthen the intellectual property foundation for investigational Revita® as the Company advances toward a planned U.S. Food and Drug Administration (FDA) De Novo marketing submission for post-GLP-1 weight maintenance.

The patent developments build on positive six-month results from the REMAIN-1 Pivotal Cohort and recently announced market research identifying patient interest in a one-time procedural approach to maintaining weight loss after GLP-1 therapy. Together, these advances support Fractyl’s strategy to develop Revita as a potential new treatment option for patients seeking to preserve the weight loss they achieved with medication.

The U.S. Patent and Trademark Office (USPTO) has issued a patent covering aspects of Revita’s single-use catheter and allowed a patent application covering how the system controls thermal energy during treatment. These developments complement an existing console patent and broader issued treatment-method claims that are not limited to any specific energy modality.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.